An open, parallel, randomized, comparative, multicenter study to evaluate the cost-effectiveness, performance, tolerance, and safety of a silver-containing soft silicone foam dressing (intervention) vs silver sulfadiazine cream

Silverstein Pet al. Journal of Burn Care & Research. 2011;32(6): 617-26.

# Aims

To compare the incremental costs (direct and indirect) and healing outcomes of Mepilex<sup>®</sup> Ag with silver sulfadiazine (SSD) cream and to compare the two treatments in terms of their performance, tolerance, and safety, including pain.


# Method

Trial-based (multicenter, randomised controlled trial) economic evaluation study from the perspective of a healthcare provider.

Patients aged 5 years and older with partial-thickness thermal burns (2.5-20% BSA) were randomized into two groups

- 1. Mepilex<sup>®</sup> Ag
- 2. Silver sulfadiazine cream (Silvadene®)

# Results



## Pain

**Mepilex®** Ag was associated with less pain during dressing application (p=0.018) and during wear (p=0.048) compared to SSD at the end of week one.

Infectious complications were similar in the two treatment groups.

Mepilex<sup>®</sup> Ag proved to be as effective as silver sulfadiazine in healing time for the treatment of partial-thickness thermal burns. Mepilex<sup>®</sup> Ag was associated with reduced hospital stay, decreased pain, lower costs and ease of application compared to SSD.

### Outcomes measured


- The investigator made a subjective assessment of treatment efficacy at each formal assessment (excluding baseline) using a ranking system in terms of:
  - percentage of healing
  - ease of application
  - patient anxiety and pain during dressing changes (John Hopkins visual analogue scale)
  - dressing adherence to the wound bed and bleeding on dressing removal
  - flexibility and conformability of the dressing
- Patients recorded pain at dressing change, during wear and during application (Wong Baker Faces scale for children, Johns Hopkins visual analogue scale for adults) and rated their apprehension during dressing change, ease of movement, stinging or burning during dressing wear.
- Microbiological swabs were taken at baseline and subsequently as required.
- Time to discharge was recorded.
- Cost-related data were recorded at each dressing change.

### Additional results

- 100 patients were randomised:
  - Mepilex® Ag (n=49)
  - SSD (n=51)

#### Health costs and resources used

Total cost of care for Mepilex<sup>®</sup> Ag and SSD treatment groups:



Cost-effectiveness for each treatment regime:

	Mepilex® Ag (n=47)	SSD (n=51)
Total cost of care (US\$), mean (SD)	309 (144)	514 (282)
Full re-epithelialisation in 21 days, n (%)	38 (78.3)	34 (66.2)
Average cost- effectiveness (US\$) (95% CI)*	395 (344–450)	776 (659–892)
Incremental cost- effectiveness ratio (US\$)**	-1688	

\*Calculated from the total cost of care, divided by the proportion of patients with full re-epithelialisation.

\*\*Calculated from the difference in total cost of care, divided by the difference in the proportion of patients with full re-epithelialisation.

## Ease of use

Clinicians considered Mepilex<sup>®</sup> Ag to be superior to SSD in terms of ease of application (p=0.028) and flexibility (p=0.038).

#### www.molnlycke.com.au | www.molnlycke.co.nz

You will be required to input the following code **1FtYrV** or your **AHPRA registration number** to access our websites. Mölnlycke, 12 Narabang Way, Level 4, Belrose, NSW, 2085. Phone 1800 005 231. New Zealand Orders & Enquiries 0800 005 231, www.molnlycke.co.nz. The Mölnlycke, Mepilex and Mepitel trademarks, names and logos are registered globally to one or more of the Mölnlycke Health Care Group of Companies. © 2024 Mölnlycke Health Care. All rights reserved. AUWC\_001165

